Form 4: ADMA Biologics COO Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Kaitlin M. Kestenberg-Messina, COO and SVP of Compliance at ADMA Biologics, acquired stock options and restricted stock units (RSUs) on February 19, 2025, according to a Form 4 filing.
Summary
- Kaitlin M. Kestenberg-Messina, the COO and SVP of Compliance at ADMA Biologics, Inc., filed a Form 4 indicating changes in beneficial ownership.
- On February 19, 2025, Kestenberg-Messina acquired 77,784 restricted stock units (RSUs) and stock options for 116,279 shares.
- The RSUs vest quarterly over four years from the grant date, contingent upon continued service.
- The stock options vest over four years, with 25% vesting on the one-year anniversary and the remaining 75% vesting monthly over the subsequent three years, becoming fully vested on February 19, 2029.
- Following the reported transactions, Kestenberg-Messina beneficially owns 524,016 shares of common stock, including unvested RSUs from previous grants.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices, aligning management interests with shareholders through equity ownership.
Positives
- The grant of RSUs and stock options aligns the executive's interests with those of the shareholders.
- The vesting schedules of the RSUs and stock options incentivize continued service and performance.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The grant of equity to executives can positively impact shareholder value by aligning management's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| February 25, 2021 | Grant date of 5,000 unvested RSUs that vest quarterly over four years. |
| March 7, 2022 | Grant date of 20,000 unvested RSUs that vest quarterly over four years. |
| March 6, 2023 | Grant date of 71,250 unvested RSUs that vest quarterly over four years. |
| July 24, 2023 | Grant date of 22,500 unvested RSUs that vest quarterly over four years. |
| April 1, 2024 | Grant date of 192,320 unvested RSUs that vest quarterly over four years. |
| February 19, 2025 | Date of transaction: Grant of 77,784 RSUs and stock options for 116,279 shares. |
| February 19, 2029 | Date when stock options become fully vested. |
| February 21, 2025 | Date of Form 4 filing. |
Keywords
ADMA Biologics, Form 4, Kestenberg-Messina, Restricted Stock Units, Stock Options, Beneficial Ownership, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.